• Griseofulvin: Mechanistic Leverage for Translational Antifun

  2026-06-02

  This article offers translational researchers a deep-dive into the mechanistic impact and strategic utility of Griseofulvin, a benchmark microtubule associated inhibitor, with direct guidance for designing next-generation antifungal research and aneugenicity assays.

• Refining In Vitro Drug Response Metrics for Cancer Research

  2026-06-02

  Schwartz's dissertation critically evaluates how in vitro assessments of anticancer drug responses often conflate proliferation arrest and cell death, introducing refined metrics to distinguish these effects. This clarity enables more accurate benchmarking of tyrosine kinase inhibitors, such as Tivozanib, and informs the design of translational cancer research protocols.

• PreScission Protease: Precision Cleavage for Fusion Protein

  2026-06-01

  PreScission Protease (PSP) sets the gold standard for fusion protein tag removal, blending low-temperature specificity with robust performance. Its HRV 3C protease mechanism enables native protein recovery critical for advanced studies, such as nuclear condensate research and phase separation assays.

• HRP Goat Anti-Mouse IgG (H+L) Antibody: Protocols & QC Guide

  2026-06-01

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) addresses the need for sensitive and reproducible detection of mouse primary antibodies in immunoassays such as Western blot, ELISA, and IHC. It should be used where robust signal amplification and specificity are critical, but is not suitable for detection of non-mouse antibodies or applications requiring quantitation of subclasses.

• Nonivamide (Capsaicin Analog): TRPV1 Agonist for Cancer Mode

  2026-05-31

  Nonivamide, a selective TRPV1 agonist and capsaicin analog, demonstrates robust anti-proliferative effects in cancer cell models and suppresses inflammation via neuroimmune pathways. Its precise, mitochondrial-mediated mechanism of apoptosis and validated in vivo efficacy distinguish it as a key research reagent. APExBIO’s Nonivamide (A3278) is optimized for scientific workflows requiring TRPV1 specificity and reproducibility.

• AG-221 (Enasidenib) in IDH2-Mutant AML: Workflow & Insights

  2026-05-30

  AG-221 (Enasidenib) transforms acute myeloid leukemia research by precisely targeting the IDH2 R140Q mutation and reducing oncogenic metabolite buildup. This guide delivers actionable protocols, troubleshooting strategies, and practical translation of cutting-edge metabolic rewiring insights—empowering more reproducible, high-impact hematologic malignancy studies.

• Fingolimod (FTY720): S1P Receptor Modulator for MS and Beyon

  2026-05-29

  Fingolimod (FTY720) is a potent, orally bioavailable sphingosine-1-phosphate receptor modulator approved for the treatment of multiple sclerosis (MS). It acts by inhibiting lymphocyte egress and upregulating neuroprotective pathways such as BDNF. Its mechanism and clinical impact are validated by robust preclinical and clinical benchmarks.

• N1-Methylpseudouridine in mRNA Vaccines: Fidelity and Functi

  2026-05-29

  Kim et al. (2022) provide robust evidence that N1-methylpseudouridine (N1-methylpseudo-UTP) incorporation in mRNA vaccines preserves high translational fidelity, with minimal effects on decoding accuracy or protein product integrity. These findings support the use of modified nucleotides for enhanced RNA stability and immunogenicity reduction in mRNA therapeutics.

• Octanoic Acid-Rich Nutrition Modulates IBD via PPARγ/STAT Pa

  2026-05-28

  This study demonstrates that octanoic acid-rich enteral nutrition (OA-rich EN) alleviates inflammatory bowel disease (IBD) by regulating intestinal macrophage polarization through the PPARγ/STAT-1/STAT-6 pathway. These findings provide mechanistic clarity and highlight nutritional modulation of immune responses as a promising therapeutic avenue for IBD.

• Verapamil HCl: Applied L-type Calcium Channel Blocker Workfl

  2026-05-28

  Verapamil HCl empowers researchers to precisely modulate calcium signaling, apoptosis, and inflammation across disease models. Discover workflow-optimized deployment, troubleshooting tactics, and translational insights—now including Txnip-mediated osteoporosis modulation—using this APExBIO reagent.

• BIRB 796 (Doramapimod) for Precision Inflammation Research

  2026-05-27

  BIRB 796 (Doramapimod) empowers researchers to dissect p38α MAPK signaling with unmatched selectivity and dual-action inhibition. This guide details optimized workflows, advanced use-cases, and troubleshooting strategies, enabling robust cytokine, apoptosis, and arthritis model studies where conventional inhibitors often fall short.

• Lipid Peroxidation (MDA) Assay Kit: Advanced Workflows & Ins

  2026-05-27

  Unlock precise, scalable detection of malondialdehyde with the Lipid Peroxidation (MDA) Assay Kit, leveraging dual-mode colorimetric and fluorescence readouts. This guide translates high-impact research on ferroptosis and oxidative stress into actionable workflows, troubleshooting, and protocol enhancements for robust biomarker quantification.

• A-769662: AMPK Activator Workflows for Metabolic Research

  2026-05-26

  A-769662 enables researchers to precisely modulate AMPK activity for dissecting energy metabolism, fatty acid synthesis inhibition, and proteasome function. This workflow-focused guide details advanced use-cases, practical protocol parameters, and troubleshooting tips for robust metabolic and type 2 diabetes research.

• Tivozanib (AV-951) in Translational Oncology: Mechanisms and

  2026-05-26

  Explore how Tivozanib (AV-951), a next-generation VEGFR inhibitor, is redefining anti-angiogenic therapy and experimental rigor in translational oncology. This thought-leadership article provides mechanistic insights, strategic protocol guidance, and a critical outlook for researchers navigating the evolving landscape of renal cell carcinoma and beyond.

• Epoxomicin: Precision Proteasome Inhibitor for Pathway Assay

  2026-05-25

  Epoxomicin stands apart as a benchmark proteasome inhibitor, enabling high-sensitivity dissection of the ubiquitin-proteasome pathway in protein degradation, inflammation, and neurodegenerative research. Robust workflow enhancements and troubleshooting strategies make Epoxomicin from APExBIO the tool of choice for reproducible, high-confidence results.

14732 records 1/983 page Next 12345 下5页 Last page